Claims for Patent: 4,229,571

Summary for Patent: 4,229,571

Title:	Glucocorticoid sparing factor and process for the production of the same
Abstract:	A glucocorticoid sparing factor (GSF) which amplifies to liver enzyme induction which is caused in glucocorticoid and a process for the production of GSF are disclosed. GSF can be isolated from the culture broth of a microorganism of the Family Enterobacteriaceae.
Inventor(s):	Katsunuma; Nobuhiko (Shomachi, Tokushima-shi, Tokushima-ken, JP)
Assignee:
Application Number:	05/933,083
Patent Claims:	1. A glucocorticoid sparing factor characterized in that: it is a colorless and acidic substance produced in a culture broth of a microorganism of the Family Enterobacteriaceae and is easily soluble in water and in diluted aqueous acid or alkali; it is positive to 1,10-phenanthroline reaction, Orcinol reaction and Anthrone reaction and negative to Folin-Thiocalt reaction and Elson-Morgan reaction; it has a molecular weight between about 800 and about 1,500; it is an oligosaccharide having N-acetylneuraminic acid, pentose, hexose and a primary amine as constructing moieties; it indicates in vivo an amplifying action in the induction if tyrosine transaminase and leucine transaminase by glucocorticoid in the liver of adrenalectomized rat, with said amplifying action being deactivated by the action of .alpha.-glucosidase, but not being affected by the action of .alpha.-amylase, neuraminidase, hyaluronidase, lysozyme, chymotripsin, trypsin, pepsin, proteinase, papain, collagenase, aminopeptidase M, carboxypeptidases A and B, leucine-aminopeptidase, deoxyribonuclease 1, ribonuclease T.sub.1 +A, acid phosphatase or alkali phosphatase; it does not influence induction of liver tyrosine transaminase in adrenalectomized rat when administered alone nor does it influence such induction by glycagon or insulin; it indicates an amplifying action on the induction of tyrosine transaminase by glycocorticoid in an in vitro system using the liver of an adrenalectomized rat under the perfusion method when added to the system prior to or at the same time as the administration of glucocorticoid; it is stable for more than 6 months at -20.degree. C; it is stable for minimum 48 hours in a buffer solution having a pH of 4.2-9 at 37.degree. C.; it is deactivated to form reducing sugar when heated at 105.degree. C. for 12 hours in 6N hydrochloric acid; it has shoulder at 265 nm in untraviolet absorption spectrum and, after purification in a proper manner, a sharp peak appears at the same wavelength; and it has an Rf of about 0.16 as measured by ascending method using filter paper and acetic acid-n-butanol-water (3:12:5, v/v) as a developing agent. 2. A process for the production of the glucocorticoid sparing factor according to claim 1 which comprises cultivating a microorganism of the Family Enterobacteriaceae and isolating said factor from the culture broth. 3. A process for the production of the glucocorticoid sparing factor according to claim 1 which comprises cultivating a microorganism of the Family Enterobacteriaceae, extracting the bacterial substance from the propagated cells by destructing said cells, deproteinizing the extract, causing the extract to be adsorbed on activated charcoal, eluting the adsorbate with an organic solvent-containing solution, and purifying the eluate with gel filtration or column chromatography on ion exchange resin. 4. A process in accordance with claim 3 wherein said organic solvent-containing solution is selected from the group consisting of 0.2 N aqueous potassium hydroxide-acetone (3:7, v/v) and 10-30% aqueous ethanol. 5. A process in accordance with claim 3 wherein said gel filtration is effected with the use of a filter medium selected from the group consisting of those under the trade names of Sephadex G, Sephadex LH-20 and Polystyrene gel G 3000S. 6. A process in accordance with claim 3 wherein said ion exchange resin for the column chromatography is selected from the group consisting of DEAE cellulose and those under the trade name of Dowex 50 W. 7. A process in accordance with claim 3 wherein said microorganism of the Family Enterbacteriaceae is selected from the group consisting of those belonging to the general Escherichia, Aerobacter, Klebsiella, Paracolobactrum, Alginobactor, Erwinia, Serratia, Salmonella, Proteus and Shigella. 8. A process in accordance with claim 3 wherein said microorganism of the Family Enterobacteriaceae is selected from the group consisting of Escherichia coli, Erwinia aroideae, Erwinia carotovora, Serratia marcesens, Proteus mirabilis, Proteus vulgaris, Proteus morganii and Aerobactor aerogenes.

Details for Patent 4,229,571

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	05/05/2004		1997-10-21
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	12/02/2004		1997-10-21
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	10/26/2004		1997-10-21